Dementia

DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI

Retrieved on: 
Tuesday, April 23, 2024
Brain, University, Dementia, AI, Government, Sport, Health, BRAIN, Research, Mental health, Drexel University

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, today announced that BRAIN AGE® Brain Health AI, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score, is available to Canadian-based clinics focusing on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical and academic research for neurological and cognitive disorders.

Key Points: 
  • TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, today announced that BRAIN AGE® Brain Health AI, a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score, is available to Canadian-based clinics focusing on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical and academic research for neurological and cognitive disorders.
  • BRAIN AGE® Brain Health AI could complement these efforts in Canada to improve overall brain health.
  • BRAIN AGE® Brain Health AI is a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score.
  • Based on research and development at Drexel University and the University of Miami, BRAIN AGE® Brain Health AI combines a brain age estimation and brain health assessment tool with the aim to ‘raise a red flag’ for potential brain health issues.

Unlocking the Secrets to a Sharper Mind and Healthier Cells

Retrieved on: 
Wednesday, April 17, 2024
Brain, Oxidative stress, Dementia, CDC, Motivation, Cell, Research, History, Nutrient, Cell membrane, Ageing

“Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.

Key Points: 
  • “Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.
  • These products replenish essential nutrients, enhance cellular repair mechanisms, and protect against oxidative stress.
  • They are pivotal for maintaining cell membrane integrity, which is essential for the brain cells that manage information processing and cognitive performance.
  • Return Healthy’s Cell Stabilization Plan is a testament to the company’s commitment to empower individuals to take control of their healthspan with preventive self-care and advanced nutritional support.

Elara Caring Partners with Constant Therapy to Deliver First AI-Driven Speech-Language and Cognitive Therapy at Scale

Retrieved on: 
Wednesday, April 17, 2024
Brain, Stroke, Neurological disorder, Health, Population health, Partnership, Dementia, Patient, Caregiver, DSM-IV codes, Constant, Pharmaceutical industry

Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.

Key Points: 
  • Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.
  • With the partnership, Elara clinicians can now deliver a highly-personalized course of therapeutic exercises – and measure patient progress – to best meet the needs of patients recovering from conditions such as stroke, brain injury or dementia.
  • Simultaneously, Elara patients are given unlimited access to the Constant Therapy mobile app – allowing them to maintain engagement with their therapy program outside of their scheduled clinical visits.
  • “Elara Caring is well recognized for its use of advanced technology and data insights that help proactively treat and monitor patients,” said Mark Salley, VP of Innovations and Rehab Solutions, Elara Caring.

Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules

Retrieved on: 
Wednesday, April 17, 2024
Essential, Johnson & Johnson, Dementia, CNS, Patient, Acquisition, Caregiver, Alzheimer's disease, Central nervous system

Egham, UK – 17 April 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.

Key Points: 
  • Egham, UK – 17 April 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
  • Under the terms of the acquisition, Essential Pharma has acquired rights to Reminyl® oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.
  • The acquisition of Reminyl® represents further validation of Essential Pharma’s status as a trusted partner in ensuring the sustained supply of essential medicines to patients, healthcare providers and carers.
  • Emma Johnson, CEO of Essential Pharma, commented: “Our acquisition of rights to Reminyl® in these markets will ensure Alzheimer’s patients and caregivers in those regions have continued access to this vital medicine.

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Retrieved on: 
Tuesday, April 16, 2024
GRN, Brain, FTD, United, Hospital, Dementia, Frontotemporal dementia, Spine, Thalamus, Patient, Clinical trial, Medical device

SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.

Key Points: 
  • SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.
  • “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families.
  • The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
  • “We are proud to support AviadoBio and the team at Mazowiecki Szpital Bródnowski Hospital, as well as other clinical trial sites to come in Europe and the United States.”
    More information about the ASPIRE-FTD study can be found at https://clinicaltrials.gov/study/NCT06064890.

UsAgainstAlzheimer’s Launches 2024 Brain Health Academy

Retrieved on: 
Tuesday, April 16, 2024
Brain, Nutrition, Risk, Dietitian, Eisai, Doctor, Dementia, Growth, Tivity Health, Ageing, Patient, Society, AARP, American Heart Association

Each of the hour-long virtual sessions will be recorded and available for on-demand viewing up to 60 days after the live presentation.

Key Points: 
  • Each of the hour-long virtual sessions will be recorded and available for on-demand viewing up to 60 days after the live presentation.
  • A testament to the Academy’s impact, more than 5,300 individuals benefitted from the free, evidence-based education program.
  • More than half of participants reported a significant shift in their approach to brain health and how they discuss risk factors and dementia with their patients.
  • “With educational programs like the Brain Health Academy, we can empower health care professionals to better serve those whom they serve by counseling them about the importance of promoting and protecting their brain health and reducing their risk of developing brain disease.”
    The Brain Health Academy is made possible through its collaborative efforts with partners, including the Academy of Doctors of Audiology, Academy of Nutrition and Dietetics, American Society on Aging, AARP, American Academy of Sleep Medicine, American Heart Association, American College of Lifestyle Medicine, Centers for Disease Control and Prevention, Eisai, Humana, Physical Activity Alliance, Tivity Health, and USAging.

Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement

Retrieved on: 
Monday, April 15, 2024
Sale, Brain, Pain, Myalgia, Stroke, Woman, Tissue, Dietary supplement, Infertility, Infection, Testosterone, DSM-IV codes, Pelvic floor dysfunction, Male, Climacteric, Insomnia, System, Dementia, Dysmenorrhea, Erectile dysfunction, Lipid, Anxiety, Toothache, Oxygen, Headache, Acquisition, Memory, Libido, Tribulus terrestris, Tracheobronchitis, Fever, Metamizole

HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

Key Points: 
  • HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.
  • The acquisition includes full dossiers for each product, which will allow NKPH to quickly register them for sale once the company has finalized the branding of each.
  • The technologies, which were purchased through NKPH’s subsidiary, Nika Europe Ltd., have a proven market track record, as each of them satisfy an important health need of the population.
  • MENTHYL VALERATE 60mg is an over-the-counter drug with a positive effect on the central nervous and cardiovascular systems.

This Older Californians Month, Start the Conversation with Your Family to Connect with California’s Aging Resources

Retrieved on: 
Wednesday, May 1, 2024
Public Policy, Government, Women, Seniors, State, Local, Men, Healthcare Reform, Family, Consumer, MPA, Social isolation, Loneliness, Dementia, CDA, Mental Health Awareness Month, Disability, California Department, Health, Insurance, Depression, Elder abuse, Friends, Senior counsel, Caregiver, Nursing

In support, the California Department of Aging (CDA) launched the "Start the Conversation" campaign to encourage and support connections, helping older adults, adults with disabilities, family caregivers, and loved ones connect with the wide variety of aging services offered in California.

Key Points: 
  • In support, the California Department of Aging (CDA) launched the "Start the Conversation" campaign to encourage and support connections, helping older adults, adults with disabilities, family caregivers, and loved ones connect with the wide variety of aging services offered in California.
  • The enhanced Aging in California Resource Guide , in print and online this month, provides Californians a starting point to connect with information and support.
  • "Older Californians offer so much to our state, and California offers a variety of resources to support this growing population," said CDA Director Susan DeMarois.
  • "The theme of connection is an excellent reminder for us all to reach out and connect with the older adults in our lives.

Navy Federal Credit Union Honors Servicemembers and Military Families Who Go Above and Beyond for Military Appreciation Month

Retrieved on: 
Wednesday, May 1, 2024
Banking, Professional Services, Other Consumer, Women, Men, Veterans, Family, Military, Defense, Consumer, Finance, Army, Gambling, Silver, Navy Federal Credit Union, Credit union, Heart, Flower, ESA, Dementia, Navy, Tax, Air National Guard, NCUA, Workforce, Multimedia, Credit, Active duty, ID, IRA, Coast guard, APY, Nursing

Navy Federal Credit Union is launching celebratory activities and member deals to honor Active Duty servicemembers, Veterans and their families for Military Appreciation Month.

Key Points: 
  • Navy Federal Credit Union is launching celebratory activities and member deals to honor Active Duty servicemembers, Veterans and their families for Military Appreciation Month.
  • View the full release here: https://www.businesswire.com/news/home/20240501187645/en/
    Navy Federal Credit Union is launching celebratory activities and member deals to honor Active Duty servicemembers, Veterans and their families for Military Appreciation Month.
  • Navy Federal Credit Union: Established in 1933 with only seven members, Navy Federal now has the distinct honor of serving more than 13 million members globally and is the world’s largest credit union.
  • Navy Federal Credit Union employees, contractors, and their immediate family members are not eligible to participate in this promotion.

Silverado Memory Care Nexus Program Honored by Argentum With “Best of the Best” Award

Retrieved on: 
Tuesday, April 30, 2024
Seniors, Practice Management, Nursing, Managed Care, General Health, Health, Consumer, Other Health, Nexus, Argentum, NEXUS, Dementia, GNP, Senior, RN, Amnesia

Silverado Memory Care , a leading provider in senior living and memory care, is proud to announce its Nexus Program designed to preserve cognitive functioning and slow the progression of dementia, has been recognized with Argentum’s “Best of the Best” Award, for its unique approach to supporting an active, brain-healthy lifestyle for individuals living with the early stages of dementia.

Key Points: 
  • Silverado Memory Care , a leading provider in senior living and memory care, is proud to announce its Nexus Program designed to preserve cognitive functioning and slow the progression of dementia, has been recognized with Argentum’s “Best of the Best” Award, for its unique approach to supporting an active, brain-healthy lifestyle for individuals living with the early stages of dementia.
  • “It’s exciting for us to be recognized alongside fellow industry leaders who are paving the way for the future of senior living,” said Loren Shook, Chief Executive Officer and Chairman of Silverado .
  • The “Best of the Best” Award recognizes innovative new programs and services that are working to improve the future of, or solve particular challenges within, senior living.
  • For more information about Silverado and the Nexus Program, visit www.silverado.com/nexus-at-silverado/ .